Hepatocellular Carcinoma, Liver Cancer, Adult, Liver Cell Carcinoma
Conditions
Keywords
TCR T cells, Hepatocellular Carcinoma, HBV, Hepatitis B virus
Brief summary
This is an open-label and multi-center Phase 2 study to evaluate the safety and efficacy of autologous T-cells transfected with mRNA encoding Hepatitis-B virus (HBV)-antigen-specific T cell receptor (TCR) (LioCyx-M) as monotherapy or as combination with lenvatinib for the treatment of advanced HBV-related hepatocellular carcinoma (HCC).
Interventions
BIOLOGICALLioCyx-M
HBV antigen specific TCR redirected T cells
DRUGLenvatinib
12 mg once daily for patients ≥60 kg, 8 mg for patients \<60kg by oral
Sponsors
Lion TCR Pte. Ltd.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Eastern Cooperative Oncology Group (ECOG) performance status ≤1 2. Advanced HCC with diagnosis confirmed by histology/ cytology or clinically by AASLD criteria in cirrhotic patients. 3. Disease that is not amenable to curative surgical and/or locoregional therapies, or progressive disease after surgical and /or locoregional therapies 4. Patients who failed first-line systemic therapy for HCC 5. Serum HBsAg positivity 6. Non-cirrhotic or compensated cirrhosis Child-Pugh A (5 - 6 points) 7. HLA class 1 profile matching HLA-class I restriction element of the available T cell receptor
Exclusion criteria
1. Brain metastasis 2. Second primary malignancy that is clinically detectable at the time of consideration for study enrolment, except for in situ carcinoma of the cervix, non-melanoma skin carcinoma localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer and superficial bladder tumours. 3. Lack of peripheral venous or central venous access or any condition that would interfere with drug administration or collection of study samples 4. History of severe allergic anaphylactic reactions to T cell therapy products and/or lenvatinib 5. Local or loco-regional therapy of intrahepatic tumour lesions (e.g. surgery, radiation therapy, hepatic arterial embolization, chemoembolization, radiofrequency ablation, percutaneous ethanol injection, or cryoablation) must have been completed ≥4 weeks before the first infusion of LioCyx-M. 6. Concurrent administration of any other anti-tumour therapy, including cytotoxic chemotherapy, tyrosine kinase inhibitor therapy, and immunotherapy. 7. Treatment with anticancer therapy, including investigational therapy, within 2 weeks prior to first infusion. For prior therapies with a half-life longer than 3 days, discontinuation of the therapy must have occurred at least 28 days prior to leukapheresis. 8. Treatment with other investigational therapy within 28 days prior to initiation of study treatment. Patients participating in surveys or observational studies are eligible to participate in this study. 9. Likelihood to require any immunosuppressive treatments during the period of the clinical trial (Localized steroid use should be allowed) 10. Human immunodeficiency virus (HIV) positive or active infection requiring treatment (except for HBV) 11. Significant cardiovascular disease (such as New York Heart Association (NYHA) Functional Classification Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident within 3 months prior to initiation of study treatment), unstable arrhythmia, or unstable angina 12. Uncontrolled hypertension, defined as systolic blood pressure \>160 mmHg or diastolic pressure \>110 mmHg, despite optimal medical management
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Assessments of adverse events/serious adverse events | Up to 4 years from study treatment initiation | To evaluate the safety of LioCyx-M as a monotherapy and in combination with lenvatinib |
| Objective response rate (ORR) | Up to 4 years from study treatment initiation | To evaluate the anti-tumor efficacy of LioCyx-M as a monotherapy and in combination with lenvatinib |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression free survival (PFS) | Up to 4 years from study treatment initiation | To evaluate the anti-tumor efficacy of LioCyx-M as a monotherapy and in combination with lenvatinib |
| Time to radiographic progression (TTRP) | Up to 4 years from study treatment initiation | To evaluate the anti-tumor efficacy of LioCyx-M as a monotherapy and in combination with lenvatinib |
| Duration of response (DoR) | Up to 4 years from study treatment initiation | To evaluate the anti-tumor efficacy of LioCyx-M as a monotherapy and in combination with lenvatinib |
| Overall survival (OS) | Up to 4 years from study treatment initiation | To evaluate the anti-tumor efficacy of LioCyx-M as a monotherapy and in combination with lenvatinib |
Contacts
Primary ContactRegina Wong
Outcome results
None listed